Lifeward Reports Q4, Details Strategic Expansion with Exoskeleton Acquisition and Up to $47M Oramed Funding
LFWD sits 69% above its 52-week low of $4.14.
Summary
Lifeward Ltd. (LFWD) reported its fourth quarter and full year 2025 financial results, emphasizing its strategic transformation into a diversified biomedical innovation company. The report highlights the acquisition of a new powered upper-body exoskeleton technology, which complements its existing ReWalk platform and leverages its established infrastructure. Crucially, the company detailed the financial aspects of its strategic partnership with Oramed Pharmaceuticals (ORMP), where Lifeward will acquire Oramed's POD™ technology platform and receive up to $47 million in additional funding from Oramed, which will also fund clinical development. This funding, along with lower operating expenses, positions Lifeward on a clear path to becoming cash flow positive. While shareholder approval for the Oramed transaction was previously announced, the specific funding details and the new exoskeleton acquisition are highly material for a company of Lifeward's size, significantly expanding its innovation pipeline and strategic direction. Traders will be watching for the closing of the Oramed transaction and the commercial launch of the new exoskeleton technology.
At the time of this announcement, LFWD was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $4.14 to $23.04. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.